Half-life
6–8 days (DAC modification)
Evidence Level
Moderate Evidence
Mechanism of Action
Modified GHRH analogue. DAC modification allows covalent binding to plasma albumin, extending half-life from minutes to days. Stimulates pituitary GH secretion in a physiologically-timed manner.
Published Research Ranges & Study Context
Studies have administered: 1–2mg weekly in research publications
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
Studies demonstrate sustained elevation of GH and IGF-1 levels for up to 14 days per injection. Human trials show favorable GH/IGF-1 pharmacokinetics.
Moderate Evidence
Phase 1/2 human trials available
Side Effects Observed in Research
Injection site reactions, water retention, carpal tunnel syndrome at higher ranges in studies
Available Configurations (SKU Reference)
CD5
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on CJC-1295 w/DAC — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.